Tito Carrera-Rodríguez, Servicio de Cardio-Oncología, Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC); Servicio de Cardiología, Fundación Santa Fe de Bogotá; Servicio de Hematología, CTIC Luis Carlos Sarmiento Angulo; Grupo de investigación GIGA CTIC, Universidad El Bosque. Bogotá, Colombia
Gina González-Robledo, Servicio de Cardiología, Fundación Santa Fe de Bogotá, Bogotá, Colombia
Paola Omaña, Servicio de Hematología, CTIC Luis Carlos Sarmiento Angulo; Grupo de investigación GIGA CTIC, Universidad El Bosque. Bogotá, Colombia
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy that has found in Bruton’s tyrosine kinase inhibitors an excellent tool for his treatment, with significant improvement in its overall prognosis. However, this medication has been linked to an increased risk of cardiovascular adverse events, leading to the presence of high blood pressure, atrial fibrillation, ventricular arrhythmias and/or heart failure as the most frequent. It is necessary to achieve an adequate characterization of patients in order to define together with hematologists, the best treatment strategy to achieve adequate efficacy with the best possible control of the risk of adverse cardiovascular events.
Keywords: Cardio-oncology. Cardiovascular safety. Atrial fibrillation. Leukemia. Bruton´s tirosine Kinase inhibitos (iBTK).
